• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Molecular modeling studies of HIV-1 reverse transcriptase nonnucleoside inhibitors: total energy of complexation as a predictor of drug placement and activity.人类免疫缺陷病毒1型逆转录酶非核苷类抑制剂的分子模拟研究:络合总能量作为药物定位和活性的预测指标
Protein Sci. 1995 Oct;4(10):2203-22. doi: 10.1002/pro.5560041026.
2
Structure of HIV-1 RT/TIBO R 86183 complex reveals similarity in the binding of diverse nonnucleoside inhibitors.
Nat Struct Biol. 1995 May;2(5):407-15. doi: 10.1038/nsb0595-407.
3
The structure of HIV-1 reverse transcriptase complexed with 9-chloro-TIBO: lessons for inhibitor design.与9-氯-TIBO复合的HIV-1逆转录酶的结构:抑制剂设计的经验教训。
Structure. 1995 Sep 15;3(9):915-26. doi: 10.1016/S0969-2126(01)00226-X.
4
Crystal structures of 8-Cl and 9-Cl TIBO complexed with wild-type HIV-1 RT and 8-Cl TIBO complexed with the Tyr181Cys HIV-1 RT drug-resistant mutant.与野生型HIV-1逆转录酶复合的8-氯和9-氯替博韦的晶体结构以及与Tyr181Cys HIV-1逆转录酶耐药突变体复合的8-氯替博韦的晶体结构。
J Mol Biol. 1996 Dec 20;264(5):1085-100. doi: 10.1006/jmbi.1996.0698.
5
Prediction of binding affinities for TIBO inhibitors of HIV-1 reverse transcriptase using Monte Carlo simulations in a linear response method.使用线性响应方法中的蒙特卡罗模拟预测HIV-1逆转录酶的替博韦(TIBO)抑制剂的结合亲和力。
J Med Chem. 1998 Dec 17;41(26):5272-86. doi: 10.1021/jm9804174.
6
Mechanism of inhibition of HIV-1 reverse transcriptase by nonnucleoside inhibitors.非核苷类抑制剂对HIV-1逆转录酶的抑制机制。
Science. 1995 Feb 17;267(5200):988-93. doi: 10.1126/science.7532321.
7
Relative free energy of binding and binding mode calculations of HIV-1 RT inhibitors based on dock-MM-PB/GS.基于对接-MM-PB/GS的HIV-1逆转录酶抑制剂结合的相对自由能及结合模式计算
Proteins. 2004 Nov 15;57(3):493-503. doi: 10.1002/prot.20223.
8
A single conservative amino acid substitution in the reverse transcriptase of human immunodeficiency virus-1 confers resistance to (+)-(5S)-4,5,6,7-tetrahydro-5-methyl-6-(3-methyl-2-butenyl)imidazo[4,5, 1- jk][1,4]benzodiazepin-2(1H)-thione (TIBO R82150).人类免疫缺陷病毒1型逆转录酶中的单个保守氨基酸取代赋予了对(+)-(5S)-4,5,6,7-四氢-5-甲基-6-(3-甲基-2-丁烯基)咪唑并[4,5,1-jk][1,4]苯并二氮杂卓-2(1H)-硫酮(TIBO R82150)的抗性。
Mol Pharmacol. 1993 Jan;43(1):11-6.
9
Enzymatic properties of two mutants of reverse transcriptase of human immunodeficiency virus type 1 (tyrosine 181-->isoleucine and tyrosine 188-->leucine), resistant to nonnucleoside inhibitors.1型人类免疫缺陷病毒逆转录酶的两种突变体(酪氨酸181→异亮氨酸和酪氨酸188→亮氨酸)的酶学特性,对非核苷抑制剂具有抗性。
AIDS Res Hum Retroviruses. 1994 Aug;10(8):939-46. doi: 10.1089/aid.1994.10.939.
10
Structure of HIV-1 reverse transcriptase in a complex with the non-nucleoside inhibitor alpha-APA R 95845 at 2.8 A resolution.HIV-1逆转录酶与非核苷抑制剂α-APA R 95845复合物在2.8埃分辨率下的结构
Structure. 1995 Apr 15;3(4):365-79. doi: 10.1016/s0969-2126(01)00168-x.

引用本文的文献

1
Small Molecules of Natural Origin as Potential Anti-HIV Agents: A Computational Approach.天然来源的小分子作为潜在抗HIV药物:一种计算方法
Life (Basel). 2021 Jul 20;11(7):722. doi: 10.3390/life11070722.
2
The road to new antiviral therapies.通往新型抗病毒疗法之路。
Clin Appl Immunol Rev. 2005 Jan-Feb;5(1):65-76. doi: 10.1016/j.cair.2004.10.002. Epub 2005 Jan 22.
3
Per-residue energy decomposition pharmacophore model to enhance virtual screening in drug discovery: a study for identification of reverse transcriptase inhibitors as potential anti-HIV agents.用于增强药物发现中虚拟筛选的逐残基能量分解药效团模型:作为潜在抗HIV药物的逆转录酶抑制剂鉴定研究
Drug Des Devel Ther. 2016 Apr 11;10:1365-77. doi: 10.2147/DDDT.S95533. eCollection 2016.
4
Computational drug design strategies applied to the modelling of human immunodeficiency virus-1 reverse transcriptase inhibitors.应用于人类免疫缺陷病毒-1逆转录酶抑制剂建模的计算药物设计策略。
Mem Inst Oswaldo Cruz. 2015 Nov;110(7):847-64. doi: 10.1590/0074-02760150239.
5
An allosteric modulator of HIV-1 protease shows equipotent inhibition of wild-type and drug-resistant proteases.一种HIV-1蛋白酶的变构调节剂对野生型和耐药蛋白酶具有同等效力的抑制作用。
J Med Chem. 2014 Aug 14;57(15):6468-78. doi: 10.1021/jm5008352. Epub 2014 Aug 1.
6
Nonnucleoside inhibitor binding affects the interactions of the fingers subdomain of human immunodeficiency virus type 1 reverse transcriptase with DNA.非核苷抑制剂结合会影响1型人类免疫缺陷病毒逆转录酶指状亚结构域与DNA的相互作用。
J Virol. 2004 Apr;78(7):3387-97. doi: 10.1128/jvi.78.7.3387-3397.2004.
7
Hybrid Ty1/HIV-1 elements used to detect inhibitors and monitor the activity of HIV-1 reverse transcriptase.用于检测抑制剂并监测HIV-1逆转录酶活性的杂交Ty1/HIV-1元件。
Proc Natl Acad Sci U S A. 1998 Nov 10;95(23):13905-10. doi: 10.1073/pnas.95.23.13905.
8
In search of a selective antiviral chemotherapy.寻找一种选择性抗病毒化疗方法。
Clin Microbiol Rev. 1997 Oct;10(4):674-93. doi: 10.1128/CMR.10.4.674.

本文引用的文献

1
Resistance of clinical isolates of human immunodeficiency virus to antiretroviral agents.人类免疫缺陷病毒临床分离株对抗逆转录病毒药物的耐药性。
Antimicrob Agents Chemother. 1993 Jun;37(6):1207-13. doi: 10.1128/AAC.37.6.1207.
2
A priori prediction of activity for HIV-1 protease inhibitors employing energy minimization in the active site.利用活性位点能量最小化对HIV-1蛋白酶抑制剂活性进行先验预测。
J Med Chem. 1995 Jan 20;38(2):305-17. doi: 10.1021/jm00002a012.
3
Amino acid substitutions in HIV-1 reverse transcriptase with corresponding residues from HIV-2. Effect on kinetic constants and inhibition by non-nucleoside analogs.
J Biol Chem. 1993 Aug 5;268(22):16571-7.
4
Crystal structure of human immunodeficiency virus type 1 reverse transcriptase complexed with double-stranded DNA at 3.0 A resolution shows bent DNA.人类免疫缺陷病毒1型逆转录酶与双链DNA复合物在3.0埃分辨率下的晶体结构显示出弯曲的DNA。
Proc Natl Acad Sci U S A. 1993 Jul 1;90(13):6320-4. doi: 10.1073/pnas.90.13.6320.
5
HIV-1-specific reverse transcriptase inhibitors show differential activity against HIV-1 mutant strains containing different amino acid substitutions in the reverse transcriptase.HIV-1特异性逆转录酶抑制剂对逆转录酶中含有不同氨基酸取代的HIV-1突变株表现出不同的活性。
Virology. 1993 Jan;192(1):246-53. doi: 10.1006/viro.1993.1027.
6
Kinetics of different human immunodeficiency virus type 1 reverse transcriptases resistant to human immunodeficiency virus type 1-specific reverse transcriptase inhibitors.对1型人类免疫缺陷病毒特异性逆转录酶抑制剂耐药的不同1型人类免疫缺陷病毒逆转录酶的动力学
Mol Pharmacol. 1993 Apr;43(4):521-6.
7
Non-nucleoside inhibitors of HIV-1 reverse transcriptase: molecular modeling and X-ray structure investigations.
J Med Chem. 1993 Mar 19;36(6):726-32. doi: 10.1021/jm00058a009.
8
Potent and highly selective human immunodeficiency virus type 1 (HIV-1) inhibition by a series of alpha-anilinophenylacetamide derivatives targeted at HIV-1 reverse transcriptase.一系列靶向人类免疫缺陷病毒1型(HIV-1)逆转录酶的α-苯胺基苯乙酰胺衍生物对HIV-1具有强效且高度选择性的抑制作用。
Proc Natl Acad Sci U S A. 1993 Mar 1;90(5):1711-5. doi: 10.1073/pnas.90.5.1711.
9
Structure of HIV-1 reverse transcriptase in a complex with the non-nucleoside inhibitor alpha-APA R 95845 at 2.8 A resolution.HIV-1逆转录酶与非核苷抑制剂α-APA R 95845复合物在2.8埃分辨率下的结构
Structure. 1995 Apr 15;3(4):365-79. doi: 10.1016/s0969-2126(01)00168-x.
10
Mechanism of inhibition of HIV-1 reverse transcriptase by non-nucleoside inhibitors.非核苷类抑制剂对HIV-1逆转录酶的抑制机制
Nat Struct Biol. 1995 Apr;2(4):303-8. doi: 10.1038/nsb0495-303.

人类免疫缺陷病毒1型逆转录酶非核苷类抑制剂的分子模拟研究:络合总能量作为药物定位和活性的预测指标

Molecular modeling studies of HIV-1 reverse transcriptase nonnucleoside inhibitors: total energy of complexation as a predictor of drug placement and activity.

作者信息

Kroeger Smith M B, Rouzer C A, Taneyhill L A, Smith N A, Hughes S H, Boyer P L, Janssen P A, Moereels H, Koymans L, Arnold E

机构信息

ABL-Basic Research Program, NCI-Frederick Cancer Research and Development Center, Maryland 21702, USA.

出版信息

Protein Sci. 1995 Oct;4(10):2203-22. doi: 10.1002/pro.5560041026.

DOI:10.1002/pro.5560041026
PMID:8535257
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2142988/
Abstract

Computer modeling studies have been carried out on three nonnucleoside inhibitors complexed with human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT), using crystal coordinate data from a subset of the protein surrounding the binding pocket region. Results from the minimizations of solvated complexes of 2-cyclopropyl-4-methyl-5,11-dihydro-5H-dipyrido[3,2-b :2',3'-e][1,4] diazepin-6-one (nevirapine), alpha-anilino-2, 6-dibromophenylacetamide (alpha-APA), and 8-chloro-tetrahydro-imidazo(4,5,1-jk)(1,4)-benzodiazepin-2(1H)-thi one (TIBO) show that all three inhibitors maintain a very similar conformational shape, roughly overlay each other in the binding pocket, and appear to function as pi-electron donors to aromatic side-chain residues surrounding the pocket. However, side-chain residues adapt to each bound inhibitor in a highly specific manner, closing down around the surface of the drug to make tight van der Waals contacts. Consequently, the results from the calculated minimizations reveal that only when the inhibitors are modeled in a site constructed from coordinate data obtained from their particular RT complex can the calculated binding energies be relied upon to predict the correct orientation of the drug in the pocket. In the correct site, these binding energies correlate with EC50 values determined for all three inhibitors in our laboratory. Analysis of the components of the binding energy reveals that, for all three inhibitors, solvation of the drug is endothermic, but solvation of the protein is exothermic, and the sum favors complex formation. In general, the protein is energetically more stable and the drug less stable in their complexes as compared to the reactant conformations. For all three inhibitors, interaction with the protein in the complex is highly favorable. Interactions of the inhibitors with individual residues correlate with crystallographic and site-specific mutational data. pi-Stacking interactions are important in binding and correlate with drug HOMO RHF/6-31G* energies. Modeling results are discussed with respect to the mechanism of complex formation and the design of nonnucleoside inhibitors that will be more effective against mutants of HIV-1 RT that are resistant to the currently available drugs.

摘要

利用结合口袋区域周围蛋白质子集的晶体坐标数据,对三种与1型人类免疫缺陷病毒(HIV-1)逆转录酶(RT)复合的非核苷抑制剂进行了计算机建模研究。对2-环丙基-4-甲基-5,11-二氢-5H-二吡啶并[3,2-b:2',3'-e][1,4]二氮杂卓-6-酮(奈韦拉平)、α-苯胺基-2,6-二溴苯乙酰胺(α-APA)和8-氯-四氢-咪唑并(4,5,1-jk)(1,4)-苯并二氮杂卓-2(1H)-硫酮(替博韦)的溶剂化复合物进行最小化处理的结果表明,所有三种抑制剂都保持非常相似的构象形状,在结合口袋中大致相互重叠,并且似乎作为π电子供体与口袋周围的芳香族侧链残基相互作用。然而,侧链残基以高度特异性的方式适应每个结合的抑制剂,在药物表面周围闭合以形成紧密的范德华接触。因此,计算得到的最小化结果表明,只有当抑制剂在由从其特定RT复合物获得的坐标数据构建的位点中进行建模时,计算得到的结合能才能可靠地预测药物在口袋中的正确取向。在正确的位点,这些结合能与我们实验室测定的所有三种抑制剂的EC50值相关。对结合能成分的分析表明,对于所有三种抑制剂,药物的溶剂化是吸热的,但蛋白质的溶剂化是放热的,并且两者之和有利于复合物的形成。一般来说,与反应物构象相比,蛋白质在其复合物中能量上更稳定,而药物则不太稳定。对于所有三种抑制剂,它们在复合物中与蛋白质的相互作用非常有利。抑制剂与单个残基的相互作用与晶体学和位点特异性突变数据相关。π-堆积相互作用在结合中很重要,并且与药物的HOMO RHF/6-31G*能量相关。结合复合物形成机制以及对HIV-1 RT突变体更有效的非核苷抑制剂的设计,对建模结果进行了讨论;这些突变体对目前可用的药物具有抗性。